Garcia-Montoya, L and Emery, P orcid.org/0000-0002-7429-8482 (2021) Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 30 (11). pp. 1109-1124. ISSN 1354-3784
Abstract
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease whose main hallmark is involvement of the axial skeleton. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line treatment; however, their use is limited because of side effects. Tumor necrosis factor inhibitors (TNFi) are a safe and effective therapy, and they have been approved for the management of AS.
Areas covered
This is a review of the efficacy of TNFi in disease modification in AS. It is focused on results from early-phase clinical trials; however, it also discusses the most relevant findings in order to optimize anti-TNF treatment. A literature search was done using PubMed, Medline, Embase, Google Scholar, and Cochrane library, looking for scientific publications from inception to August 2021. Further information was retrieved from ClinicalTrial.gov and Clinicaltrialsregister.eu.
Expert opinion
TNFi have demonstrated short- and long-term improvements in all aspects of disease activity, as well as physical function in patients with AS. They have drastically revolutionized the management of the disease; and even though new drugs have become available in the market, TNFi has not been displaced for the treatment of AS, and still constitute the best alternative when NSAIDs are no-longer an option.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
Keywords: | Ankylosing spondylitis, anti-TNF, axial, clinical trial, disease modification, early phase, review, spondyloarthritis, TNF inhibitors, TNFi |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 22 Apr 2022 09:21 |
Last Modified: | 25 Jun 2023 22:57 |
Status: | Published |
Publisher: | Taylor & Francis |
Identification Number: | 10.1080/13543784.2021.2010187 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:186000 |
Downloads
Filename: 13543784.2021.pdf
Licence: CC-BY-NC-ND 4.0
Filename: 13543784.2021.pdf
Licence: CC-BY-NC-ND 4.0